Skip to main content


Idenix Falls Casualty to Gilead Hep C Hoopla

Idenix shares falls on worries that its Hep C drug may not be competitive against a more potent rival from Gilead Sciences.

Gilead Wows With New Hep C Data, Boxing Out Poor 2012 Guidance

The star of Gilead's fourth-quarter call was its Hep C drug GS-7977, helping investor overlook lower-than-expected 2012 guidance.

BioLineRx: Tuesday's Hot Hep C Drug Stock

The market's insatiable demand for Hep C speculative trades was met Tuesday by a little-known Israeli drug maker.

5 Investment Ideas From Wall Street: Jan. 24

Tiffany has more bling and old problems haunt the maker of Blackberry.

Idenix Pharma Buyout Likely: Survey

A group of Wall Street investors are bullish on Hep C drug stocks, including the belief that Idenix Pharma is the next takeover target.

Breaking News

Stock Market Today: Stocks Lower As Fed Decision Looms; ISM, JOLTs Data Rattle Bulls

Markets are treading cautiously into the start of today's crucial trading session ahead of a key Fed rate decision and the start of mega cap tech earnings after the closing bell.

Elon Musk and Jeff Bezos Praise HBO's 'The Last of Us'

The two billionaires have just sung the praises of the new hit TV series, which is an adaptation of a videogame.

AMD Stock Goes for Major Breakout After Earnings Rally

Advanced Micro Devices reported earnings strong enough to trigger a post-report rally. Now AMD stock is trying for a major breakout.

Peloton Stock Races Higher As Subscription Sales, Improving Free Cash Flow Offset Q2 Loss

"If you’ve been wondering whether or not Peloton can make an epic comeback, this quarter's results show the changes we’re making are working," said CEO Barry McCarthy